Literature DB >> 16778092

Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Paul A Bunn1, Rafal Dziadziuszko, Marileila Varella-Garcia, Wilbur A Franklin, Samir E Witta, Karen Kelly, Fred R Hirsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16778092     DOI： 10.1158/1078-0432.CCR-06-0261

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  17 in total

Review 1.  Chemoprevention for brain metastases.

Authors:  Van A Trinh; Wen-Jen Hwu
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.

Authors:  Steven A Belinsky; Marcie J Grimes; Maria A Picchi; Hugh D Mitchell; Chris A Stidley; Yohannes Tesfaigzi; Meghan M Channell; Yanbin Liu; Robert A Casero; Stephen B Baylin; Mathew D Reed; Carmen S Tellez; Thomas H March
Journal:  Cancer Res       Date:  2011-01-11       Impact factor: 12.701

Review 3.  Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Joshua A Roth; Josh J Carlson
Journal:  Clin Lung Cancer       Date:  2011-07-01       Impact factor: 4.785

Review 4.  [Molecular diagnostics in lung carcinoma for therapy stratification].

Authors:  L C Heukamp; R Büttner
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

5.  Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues.

Authors:  Katalin Derecskei; Judit Moldvay; Krisztina Bogos; József Tímár
Journal:  Pathol Oncol Res       Date:  2006-12-25       Impact factor: 3.201

6.  Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma.

Authors:  C Uzan; E Darai; A Valent; O Graesslin; A Cortez; R Rouzier; P Vielh
Journal:  Virchows Arch       Date:  2009-03-18       Impact factor: 4.064

7.  Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Rafal Dziadziuszko; Yun Xiao; Sujatha Gajapathy; Margaret Skokan; Ming Lin; Vincent O'Neill; Paul A Bunn
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

8.  HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.

Authors:  Menghong Sun; Carmen Behrens; Lei Feng; Natalie Ozburn; Ximing Tang; Guosheng Yin; Ritsuko Komaki; Marileila Varella-Garcia; Waun Ki Hong; Kenneth D Aldape; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

9.  Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

Authors:  Fred R Hirsch; Roy S Herbst; Christine Olsen; Kari Chansky; John Crowley; Karen Kelly; Wilbur A Franklin; Paul A Bunn; Marileila Varella-Garcia; David R Gandara
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

10.  Review of erlotinib in the treatment of advanced non-small cell lung cancer.

Authors:  Kristen N Ganjoo; Heather Wakelee
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.